摘要
在過去的幾年裡，肺癌的發生率以及死亡率在所有癌症中一直都是名列前茅的，但這並不代表肺癌的治療完全沒有進展。對第Ⅱ期以及第Ⅲ期的非小型肺癌病人，目前術後輔助性的治療已經是完整治療的一部分。對第Ⅳ期不能開刀的病人，同步的放射治療及化學治療可予以有效的治療。化學治療一直都是第Ⅳ期肺癌病人緩和治療的主要治療藥物，不過最近新的標靶治療藥物－包括抗體類的bevacizumab和cetuxmiab，及小分子酪胺酸激脢抑制劑的erlotinib以及gefitinib都已經在治療選擇中扮演愈來愈重要的角色。尤其是當我們已經知道表皮生長因子受體的突變可以成為是否會對於erlotinib或是gefitinib一個重要的預測因子。在本篇文章中將介紹目前非小細胞肺癌的標準治療以及新的標靶藥物的使用。小細胞肺癌是一種預後較差的疾病，而且最近並沒有像非小細胞肺癌一般在治療方面有長足的進展。本篇僅就現有的小細胞肺癌之標準治療作個介紹，期待小細胞肺癌在將來也可以有更好的治療發展。
並列摘要
In the recent years, the incidence and mortality of lung cancer has stayed at the top among all cancer cases. This trend does not indicate a lack of progress in its treatment. For phase Ⅱ and phase Ⅲ patient with non-small cell lung cancer (NSCLC), postoperative adjuvant treatments have become an integral part of the complete treatment regimen. For phase Ⅲ inoperable patient, combination of Concurrent Chemoradiotherapy and Chemotherapy has been established as the best approach. The palliative treatment has continued been the chemotherapy treatment for choice for phase Ⅳ lung cancer patient. More recently a new target treatment approach involving antibodies like bevacizumab and cetuxmiab, and small molecule tyrosine kinase inhibitors like erlothinib and gefitinib has been increasingly the favorite choice among treatment options. This choice is supported by our knowledge that mutations in the epidermal growth factor receptor can be a significant predictor for erlotinib or gefitinib. This article introduces standard treatment for non-small cell lung cancer and the rising use of new target medication. On the other hand, small cell lung cancer is a disease with poor prognosis. Overall progress in therapy for non-small cell lung caner has significantly outpaced that for small cell lung cancer. This article only touches on the current standard treatment for small cell lung cancer. The author hopes that significant development will be made in the near future.
被引用紀錄
延伸閱讀
- 楊志新（2014）。肺癌治療新進展。台灣醫學，18(6)，641-643。https://www.airitilibrary.com/Article/Detail?DocID=10281916-201411-201412110011-201412110011-641-643
- 王鵬、林招膨、盧佳君（2016）。肺癌放射治療技術之比較。台灣應用輻射與同位素雜誌，12(4)，1381-1391。https://www.airitilibrary.com/Article/Detail?DocID=18156290-201612-201612300010-201612300010-1381-1391
- 施金元（2016）。肺癌治療新趨勢。聲洋防癌之聲，(153)，2-4。https://doi.org/10.6321/SYDF.201612_(153).0001
- Chang, B. S., Ger, L. P., Chen, C. L., & Lee, S. C. (1994). Lung Cancer in Patients under Age 40. Journal of Medical Sciences, 14(5), 325-340. https://www.airitilibrary.com/Article/Detail?DocID=10114564-199404-201307010007-201307010007-325-340
- HAYATA, Y. (1996). Editorial: Lung Cancer Screening. Diagnostic and Therapeutic Endoscopy, 1996(), i-i. https://doi.org/10.1155/DTE.2.i